Clinical Trial

A first proof-of-concept human study to evaluate the safety and tolerability of tezampanel in patients suffering from acute physiologic effects of opiate withdrawal.  This study will also provide a preliminary assessment on the effectiveness of glutamate receptor antagonism for amelioration of symptoms during opiate withdrawal according to the Clinicians Assessment of Opiate Withdrawal Severity (COWS) and related measures.  Preclinical data suggest that glutamate biology and its signaling pathways are intricately involved in the development and continuance of addiction.   Results of this trial may demonstrate that tezampanel liberates treatment seeking patients from the unwanted torment of withdrawal, thereby enabling a sorely needed bridge to long term sobriety.

Indiana University School of Medicine
Indiana Clinical and Translational Sciences Institute (CTSI)